advertisement-vertical Download Proto magazine app
Social Icons

When Lyme Lingers

icon-pdfpdf icon-printprint

Much recent research into Lyme only adds to its complexity. But as a public health official, Ben Beard of the CDC is also interested in progress on other fronts—for example, preventing people from getting the disease in the first place. The CDC recently contracted with Allylix, the manufacturer of a natural insecticide, nootkatone, a component of the essential oils of Alaskan yellow cedar and citrus fruits, to create a new kind of tick repellent that while toxic to ticks, is considered by the Food and Drug Administration to be a “food-grade product”—in other words, it’s thought to be safe for people, Beard says. The CDC has a licensing agreement in place and hopes to move into commercial production within five years, he says.

Also on the prevention front, public health officials hope for the return of a Lyme vaccine. In 1998, SmithKline Beecham (now GlaxoSmithKline) introduced a vaccine that was about 80% effective after three doses for at least one year. But the Advisory Committee on Immunization Practices, which advises the CDC on vaccine use, gave a tepid recommendation, suggesting use of the vaccine only in high-risk locations. Then a group of volunteers from studies of the vaccine reported arthritic symptoms. The rate of arthritis in the volunteers was the same as in the control group that didn’t get the vaccine, but sales plummeted, and the drug was withdrawn in 2002.

The CDC is currently working with Colorado State University to identify diagnostic biomarkers for Lyme—for example, a test that could detect the presence of proteins of the Lyme bacteria. But beyond these practical steps, much Lyme research will continue to focus on gaining a stronger understanding of what happens to people suffering from post-treatment Lyme-related symptoms. The CDC is funding a five-year study with New York Medical College looking at patients diagnosed with Lyme disease to find out what percentage wind up with post-Lyme disease symptoms after they finish antibiotic therapy and how those symptoms manifest themselves.

In the meantime, the ticks that transmit Lyme disease continue to spread, and the number of cases seems to be increasing. Much has been learned since the disease was first discovered almost 40 years ago, and it’s now clear what causes the infection and how to treat it effectively. However, post-Lyme disease syndromes remain problematic. As Steere puts it: “There is still much more to learn.”

previous // next
icon-pdfpdf icon-printprint

1. “Lyme Disease,” by Eugene Shapiro, The New England Journal of Medicine, May 2014. This paper walks readers through the diagnostic and prescriptive steps Shapiro takes in caring for a pregnant 32-year-old woman with a skin rash who had been bitten by a tick.

2. “Lyme Disease,” by Allen C. Steere, The New England Journal of Medicine, July 2001. This seminal review cited many times in medical literature covers how the spirochete is transmitted and goes about its business, as well as the various physical manifestations of its presence in a human host.

3. “Lyme borreliosis,” by Allen C. Steere, Harrison’s Principles of Internal Medicine, 18th Edition, Chapter 173, pp. 1401–1406. Harrison’s Principles is the most widely read book of its kind. Steere’s contribution covers guidelines for diagnosis and treatment and other essential information.

Protomag on Facebook Protomag on Twitter